Category:

South Africa

• • •

• • •

Lantronix Announces 2024 SmartEdge Channel Partner Program Award Winners

Representing Lantronix’s Global and Diverse Partner Ecosystem, SmartEdge Winners Deliver Lantronix’s Award-Winning Solutions to the World IRVINE, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) — Lantronix Inc. (NASDAQ: LTRX), a global leader of compute and connectivity IoT solutions, today announced the winners of its 2024 SmartEdge™ Partner Program Awards, highlighting its

• • • Read More • • •

Quantexa Recognized as a “Luminary” in Celent’s 2024 Insurance Fraud Detection Solutions Report

Fraud and Security solution is acknowledged for its unique features and integration of advanced AI technologies LONDON, Sept. 04, 2024 (GLOBE NEWSWIRE) — Quantexa, the global leader in Decision Intelligence (DI) solutions for the public and private sectors, today announced that its Fraud Detection solution has been awarded “Luminary” status

• • • Read More • • •

Integrated Power Services Acquires Assets of ABB Industrial Services Business

Acquisition Adds Electric Motor, Generator, Mechanical, Switchgear & Circuit Breaker Service Centers to IPS’s Growing North American Network IPS President and CEO John Zuleger GREENVILLE, S.C., Sept. 03, 2024 (GLOBE NEWSWIRE) — Integrated Power Services (IPS), a North American leader in the servicing, engineering, and remanufacturing of electrical, mechanical, and

• • • Read More • • •

Music Licensing, Inc. (OTC: SONG) Announces Acquisition of Royalty Rights to “Thank God I Got It” by Desiigner, Bolstering Its Diverse and Star-Studded Portfolio

NAPLES, Fla., Sept. 03, 2024 (GLOBE NEWSWIRE) — Music Licensing, Inc. (OTC: SONG), a leading entity in the music industry, is excited to announce the acquisition of the royalty rights to “Thank God I Got It” by the renowned artist Desiigner. This acquisition underscores Music Licensing, Inc.’s commitment to diversifying

• • • Read More • • •

Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability

REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance development of REC-994 for the potential treatment of symptomatic CCM in subsequent studies. SALT LAKE CITY, Sept. 03, 2024 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading clinical stage

• • • Read More • • •

RECENT POSTS